CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,376 shares of the company’s stock after selling 388 shares during the period. Arete Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $486,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CRSP. Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC raised its holdings in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at about $35,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Finally, Denver PWM LLC bought a new stake in CRISPR Therapeutics in the second quarter valued at $45,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock valued at $2,744,179 in the last three months. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Down 5.0 %

Shares of CRSP opened at $45.40 on Friday. The company has a 50-day moving average price of $48.83 and a two-hundred day moving average price of $51.29. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of -16.04 and a beta of 1.62. CRISPR Therapeutics AG has a 12 month low of $43.42 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the prior year, the firm earned ($1.41) EPS. Equities research analysts expect that CRISPR Therapeutics AG will post -5.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Barclays reduced their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $77.93.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.